Severe obesity is already a significant problem for many children, especially since obese children often become obese adults. Could the now popular weight-loss injection drugs be a solution for those ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent.

Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Evidence shows that blockbuster weight-loss medications can reduce obesity even in children aged 6–11, but their long-term ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Recently, GLP-1 receptor agonist medications have been prescribed more commonly, in part due to their ability to produce ...

Some people lose more weight on drugs like Ozempic, Wegovy and Saxenda than others, and a new study reveals why that might be.

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 ...